Literature DB >> 17652397

Mechanistic insights into the cure of prion disease by novel antiprion compounds.

Sarah Webb1, Tamuna Lekishvili, Corinna Loeschner, Shane Sellarajah, Frances Prelli, Thomas Wisniewski, Ian H Gilbert, David R Brown.   

Abstract

Prion diseases are fatal neurodegenerative disorders. Identification of possible therapeutic tools is important in the search for a potential treatment for these diseases. Congo red is an azo dye that has been used for many years to detect abnormal prion protein in the brains of diseased patients or animals. Congo red has little therapeutic potential for the treatment of these diseases due to toxicity and poor permeation of the blood-brain barrier. We have prepared two Congo red derivatives, designed without these liabilities, with potent activity in cellular models of prion disease. One of these compounds cured cells of the transmissible agent. The mechanism of action of these compounds is possibly multifactorial. The high affinity of Congo red derivatives, including compounds that are ineffective and are effective at the cure of prion disease, for abnormally folded prion protein suggests that the amyloidophylic property of these derivatives is not as critical to the mechanism of action as other effects. Congo red derivatives that are effective at the cure of prion disease increased the degradation of abnormal PrP by the proteasome. Therefore, the principal mechanism of action of the Congo red analogues was to prevent inhibition of proteasomal activity by PrPSc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17652397      PMCID: PMC2045489          DOI: 10.1128/JVI.01075-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

1.  Imaging linear birefringence and dichroism in cerebral amyloid pathologies.

Authors:  Lee-Way Jin; Kacey A Claborn; Miki Kurimoto; Morten A Geday; Izumi Maezawa; Faranak Sohraby; Marcus Estrada; Werner Kaminksy; Bart Kahr
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-10       Impact factor: 11.205

2.  Quantitative analysis of prion-protein degradation by constitutive and immuno-20S proteasomes indicates differences correlated with disease susceptibility.

Authors:  Stefan Tenzer; Lars Stoltze; Birgitt Schönfisch; Jörn Dengjel; Margret Müller; Stefan Stevanović; Hans-Georg Rammensee; Hansjörg Schild
Journal:  J Immunol       Date:  2004-01-15       Impact factor: 5.422

3.  Surface plasmon resonance analysis for the screening of anti-prion compounds.

Authors:  Satoshi Kawatake; Yuki Nishimura; Suehiro Sakaguchi; Toru Iwaki; Katsumi Doh-ura
Journal:  Biol Pharm Bull       Date:  2006-05       Impact factor: 2.233

4.  Clearance and prevention of prion infection in cell culture by anti-PrP antibodies.

Authors:  Joanna Pankiewicz; Frances Prelli; Man-Sun Sy; Richard J Kascsak; Regina B Kascsak; Daryl S Spinner; Richard I Carp; Harry C Meeker; Marcin Sadowski; Thomas Wisniewski
Journal:  Eur J Neurosci       Date:  2006-05       Impact factor: 3.386

5.  Current and future molecular diagnostics for prion diseases.

Authors:  Marty T Lehto; Harry E Peery; Neil R Cashman
Journal:  Expert Rev Mol Diagn       Date:  2006-07       Impact factor: 5.225

6.  Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease.

Authors:  I R Whittle; R S G Knight; R G Will
Journal:  Acta Neurochir (Wien)       Date:  2006-04-07       Impact factor: 2.216

7.  Cytosolic prion protein is not toxic and protects against Bax-mediated cell death in human primary neurons.

Authors:  Xavier Roucou; Qi Guo; Yan Zhang; Cynthia G Goodyer; Andrea C LeBlanc
Journal:  J Biol Chem       Date:  2003-08-12       Impact factor: 5.157

Review 8.  Emerging therapeutic agents for transmissible spongiform encephalopathies: a review.

Authors:  T Koster; K Singh; M Zimmermann; E Gruys
Journal:  J Vet Pharmacol Ther       Date:  2003-10       Impact factor: 1.786

9.  Disease-associated prion protein oligomers inhibit the 26S proteasome.

Authors:  Mark Kristiansen; Pelagia Deriziotis; Derek E Dimcheff; Graham S Jackson; Huib Ovaa; Heike Naumann; Anthony R Clarke; Fijs W B van Leeuwen; Victoria Menéndez-Benito; Nico P Dantuma; John L Portis; John Collinge; Sarah J Tabrizi
Journal:  Mol Cell       Date:  2007-04-27       Impact factor: 17.970

10.  Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis.

Authors:  Giovanna Mallucci; Andrew Dickinson; Jacqueline Linehan; Peter-Christian Klöhn; Sebastian Brandner; John Collinge
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

View more
  2 in total

1.  Styryl-based and tricyclic compounds as potential anti-prion agents.

Authors:  Erika Chung; Frances Prelli; Stephen Dealler; Woo Sirl Lee; Young-Tae Chang; Thomas Wisniewski
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

Review 2.  Exploring Anti-Prion Glyco-Based and Aromatic Scaffolds: A Chemical Strategy for the Quality of Life.

Authors:  María Teresa Blázquez-Sánchez; Ana M de Matos; Amélia P Rauter
Journal:  Molecules       Date:  2017-05-24       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.